EUVIMEDEUVIMED entdecken
Crossref

The deficiency of ALKBH5 promotes lenvatinib resistance and CD8+ T cell exhaustion via accumulation of the cholesterol metabolite 27HC in hepatocellular carcinoma

Jinyi Wang, Wenbo Jia, Yongping Zhou, Wenhu Zhao, Yanzhi Feng, Qingpeng Lv, Litao Liang, Deming Zhu, Chao Xu, Xiangyu Ling, Xiaoming Ai, Lianbao Kong und 1 weitere

Cancer Letters · 2026-04 · 643 · 218316

DOI: 10.1016/j.canlet.2026.218316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-04. Verfasst von Jinyi Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China; Department of Hepatobiliary and …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, Wuxi Municipal Bureau on Science and Technology, Nanjing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenvatinib is a first-line treatment option for advanced hepatocellular carcinoma (HCC), but resistance development is a challenge. A comprehensive and in-depth exploration of the molecular mechanisms underlying Lenvatinib resistance may provide novel insights and strategies for enhancing its therapeutic effectiveness. We established Lenvatinib-sensitive (LS) and Lenvatinib-resistant (LR) HCC models both in vitro and in vivo. Dot blot and Western blot analyses confirmed that the m6A methylation levels were elevated in the LR models, while the expression of ALKBH5 was significantly reduced. Lentivirus-mediated transfection of HCC cells was employed to validate the inhibitory role of ALKBH5 in Lenvatinib resistance in HCC. Mechanistically, we integrated sequencing results from mRNA and methylated RNA immunoprecipitation (MeRIP), followed by validation through RNA immunoprecipitation (RIP), MeRIP-qPCR, dual luciferase reporter assays, Liquid chromatography and tandem mass spectrometry (LC-MS/MS), Enzyme-linked immunosorbent assay (ELISA), and animal experiments (including subcutaneous tumor models and HCC orthotopic mouse models). Results confirmed that ALKBH5 deficiency in LR cells elevates m6A methylation of TBX3 mRNA, thereby enhancing its stability. TBX3 bound to the promoter region of CYP27A1, stimulating its transcription and promoting the synthesis of the cholesterol metabolite 27-hydroxycholesterol (27HC). 27HC could inhibit ferroptosis, thereby protecting LR cells from the targeting effects of Lenvatinib. Additionally, T cell-mediated tumor cell killing and flow cytometry assays evaluated that HCC-derived 27HC promoted CD8 + T cell exhaustion. Our findings indicated that the deficiency of ALKBH5 mediated the enhanced synthesis of the cholesterol metabolite 27HC, which in turn inhibited ferroptosis in HCC cells and the cytotoxicity of CD8 + T cells, leading to Lenvatinib resistance in HCC cells. While the specific role of 27HC was strongly supported, the potential contributions of other CYP27A1-derived metabolites to this phenotype remain a possibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsDrug Resistance, NeoplasmQuinolinesAlkB Homolog 5, RNA DemethylaseCD8-Positive T-LymphocytesCholesterolHumansAnimalsT-Cell ExhaustionMiceCell Line, TumorXenograft Model Antitumor AssaysMaleRNA Methylation

Stichwörter der Autor:innen

ALKBH5CD8(+) T cellCholesterol metabolismFerroptosisHepatocellular carcinomaLenvatinib resistance

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAlkB Homolog 5, RNA DemethylaseALKBH5 protein, humanCholesterol

Autor:innen und Institutionen

  • Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China; Department of Hepatobiliary and Pancreatic Surgery, Shanghai Sixth People's Hospital Affiliated to Sha…
  • Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, National Health Commissi…
  • Department of Hepatobiliary Surgery, Wuxi No.2 People's Hospital, Wuxi, Jiangsu Province, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China; Key Laboratory of Liver Transplantation, Chinese Academy of Med…
  • Department of Hepatobiliary Pancreatic Spleen Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China. Electronic address: aixiaoming0503@163.com.

Förderung

  • Graduate Research and Innovation Projects of Jiangsu Province
  • Wuxi Municipal Bureau on Science and Technology
  • Nanjing Medical University
  • National Natural Science Foundation of China
  • Jiangsu Commission of Health

Zitieren

APA

Wang, J., Jia, W., Zhou, Y., Zhao, W., Feng, Y., Lv, Q., Liang, L., Zhu, D., Xu, C., Ling, X., Ai, X., Kong, L., & Ding, W. (2026). The deficiency of ALKBH5 promotes lenvatinib resistance and CD8+ T cell exhaustion via accumulation of the cholesterol metabolite 27HC in hepatocellular carcinoma. Cancer Letters, 643, 218316. https://doi.org/10.1016/j.canlet.2026.218316

Vancouver

Wang J, Jia W, Zhou Y, Zhao W, Feng Y, Lv Q, et al. The deficiency of ALKBH5 promotes lenvatinib resistance and CD8+ T cell exhaustion via accumulation of the cholesterol metabolite 27HC in hepatocellular carcinoma. Cancer Letters. 2026;643:218316. doi:10.1016/j.canlet.2026.218316

BibTeX
@article{Wang2026,
  author = {Wang, Jinyi and Jia, Wenbo and Zhou, Yongping and Zhao, Wenhu and Feng, Yanzhi and Lv, Qingpeng and Liang, Litao and Zhu, Deming and Xu, Chao and Ling, Xiangyu and Ai, Xiaoming and Kong, Lianbao and Ding, Wenzhou},
  title = {The deficiency of ALKBH5 promotes lenvatinib resistance and CD8+ T cell exhaustion via accumulation of the cholesterol metabolite 27HC in hepatocellular carcinoma},
  journal = {Cancer Letters},
  year = {2026},
  volume = {643},
  pages = {218316},
  doi = {10.1016/j.canlet.2026.218316}
}
Kostenlos starten →